Growth Metrics

Pfizer (PFE) Dividends payables (2016 - 2025)

Pfizer (PFE) has disclosed Dividends payables for 17 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Dividends payables changed 0.33% to $2.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 billion, a 0.33% change, with the full-year FY2025 number at $2.4 billion, changed 0.33% from a year prior.
  • Dividends payables was $2.4 billion for Q4 2025 at Pfizer, roughly flat from $2.4 billion in the prior quarter.
  • In the past five years, Dividends payables ranged from a high of $2.4 billion in Q2 2025 to a low of $2.2 billion in Q3 2021.
  • A 5-year average of $2.3 billion and a median of $2.3 billion in 2022 define the central range for Dividends payables.
  • Peak YoY movement for Dividends payables: increased 4.02% in 2021, then increased 0.33% in 2025.
  • Pfizer's Dividends payables stood at $2.2 billion in 2021, then grew by 2.4% to $2.3 billion in 2022, then rose by 3.0% to $2.4 billion in 2023, then rose by 2.74% to $2.4 billion in 2024, then grew by 0.33% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Dividends payables are $2.4 billion (Q4 2025), $2.4 billion (Q2 2025), and $2.4 billion (Q4 2024).